Literature DB >> 12635503

Hepatitis C virus and arthritis.

Ignazio Olivieri1, Carlo Palazzi, Angela Padula.   

Abstract

Arthritis is one of the several autoimmune disorders induced by HCV infection. There is not a specific clinical pattern of HCV-related arthritis, but two nonerosive subsets have more frequently been described: a RA-like polyarthritis and a less common mono-oligoarthritis involving medium-sized and large joints, often showing an intermittent course. This latter form is associated with the presence of serum cryoglobulins. Because of its variable characteristics, HCV-related arthritis must be considered in the differential diagnosis of many patients having inflammatory joint involvement. Antikeratin antibodies and possibly IgA RF can be useful in distinguishing between RA and HCV-related RA-like polyarthritis. In fact, these tests are highly specific in RA patients. In any case, the search for HCV antibodies should be more widely performed in the diagnostic approach to rheumatic diseases. An association between PsA and HCV infection has been described in the literature, but the authors were unable to confirm these data. Nonsteroidal anti-inflammatory drugs, hydroxychloroquine, and low doses of corticosteroids are the cornerstones of the treatment of HCV-related arthritis. An etiologic therapy with alpha-interferon and ribavirin is useful when required by hepatic or systemic involvement; such therapy could also be considered in selected cases of isolated arthritis that are unresponsive to other drugs. Few case reports described the onset of polyarthritis after the administration of alpha-interferon for HCV-related chronic hepatitis. This topic should be more accurately studied in the future to exclude a spurious association between the two events.

Entities:  

Mesh:

Year:  2003        PMID: 12635503     DOI: 10.1016/s0889-857x(02)00097-2

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  18 in total

1.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

2.  Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

Authors:  Emilio D'Amico; Caterina Chincoli; Pierluigi Cacciatore; Gabriella di Pasqua; Luana Cosentino; Giuseppe Riario-Sforza; Ernesta Pennese; Fabio Capani; Carlo Palazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

4.  Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection.

Authors:  Amy M Joseph
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

5.  Magnetic resonance imaging classification of haemodialysis-related amyloidosis of the shoulder: risk factors and arthroscopic treatment.

Authors:  Akira Ando; Yoshihiro Hagiwara; Takuya Sekiguchi; Masashi Koide; Kenji Kanazawa; Takashi Watanabe; Eiji Itoi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-02-09       Impact factor: 4.342

6.  Purpura and serum mixed cryoglobulinemia in psoriatic arthritis.

Authors:  Carlo Palazzi; Emilio D'Amico; Ernesta Pennese; Attilio Petricca; Ignazio Olivieri
Journal:  Rheumatol Int       Date:  2006-08-10       Impact factor: 2.631

Review 7.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

8.  Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia.

Authors:  Feng-Cheng Liu; You-Chen Chao; Tsung-Yun Hou; Hsiang-Cheng Chen; Rong-Yaun Shyu; Tsai-Yuan Hsieh; Chen-Hung Chen; Deh-Ming Chang; Jenn-Haung Lai
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

9.  Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy.

Authors:  Wafaa M Ezzat; Hala M Raslan; Azza A Aly; Nahed A Emara; Manal M El Menyawi; Amr Edrees
Journal:  Rheumatol Int       Date:  2009-11-01       Impact factor: 2.631

10.  Hepatitis C virus infection in Italian patients with fibromyalgia.

Authors:  C Palazzi; E D'Amico; S D'Angelo; A Nucera; A Petricca; I Olivieri
Journal:  Clin Rheumatol       Date:  2007-10-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.